- Home
- SNSE vs AIMD Comparison
SNSE vs AIMD Comparison
Compare SNSE & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNSE
- AIMD
- Stock Information
- Founded
- SNSE 2005
- AIMD 1984
- Country
- SNSE United States
- AIMD United States
- Employees
- SNSE N/A
- AIMD N/A
- Industry
- SNSE Biotechnology: Pharmaceutical Preparations
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- SNSE Health Care
- AIMD Health Care
- Exchange
- SNSE Nasdaq
- AIMD Nasdaq
- Market Cap
- SNSE 14.5M
- AIMD 16.9M
- IPO Year
- SNSE 2021
- AIMD N/A
- Fundamental
- Price
- SNSE $9.10
- AIMD $2.64
- Analyst Decision
- SNSE Strong Buy
- AIMD
- Analyst Count
- SNSE 5
- AIMD 0
- Target Price
- SNSE $72.50
- AIMD N/A
- AVG Volume (30 Days)
- SNSE 77.5K
- AIMD 41.8K
- Earning Date
- SNSE 11-07-2025
- AIMD 11-14-2025
- Dividend Yield
- SNSE N/A
- AIMD N/A
- EPS Growth
- SNSE N/A
- AIMD N/A
- EPS
- SNSE N/A
- AIMD N/A
- Revenue
- SNSE N/A
- AIMD $110,870.00
- Revenue This Year
- SNSE N/A
- AIMD N/A
- Revenue Next Year
- SNSE N/A
- AIMD N/A
- P/E Ratio
- SNSE N/A
- AIMD N/A
- Revenue Growth
- SNSE N/A
- AIMD 70.25
- 52 Week Low
- SNSE $5.00
- AIMD $2.00
- 52 Week High
- SNSE $18.35
- AIMD $5.00
- Technical
- Relative Strength Index (RSI)
- SNSE 44.91
- AIMD 26.53
- Support Level
- SNSE $8.33
- AIMD $3.20
- Resistance Level
- SNSE $9.45
- AIMD $3.43
- Average True Range (ATR)
- SNSE 1.00
- AIMD 0.23
- MACD
- SNSE -0.27
- AIMD -0.11
- Stochastic Oscillator
- SNSE 18.90
- AIMD 3.68
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.